BioXcel Therapeutics files Chapter 11, eyes Teva asset sale
BioXcel Therapeutics has filed for voluntary Chapter 11 bankruptcy protection in the US Bankruptcy Court for the District of Delaware, simultaneously announcing an asset sale agreement with Teva Pharmaceuticals International GmbH that covers substantially all of the New Haven-based company's assets.
The centrepiece of the deal is IGALMI (dexmedetomidine) sublingual film, an approved treatment for agitation associated with schizophrenia and bipolar I or II disorder in adults, along with a pending supplemental New Drug Application (sNDA) seeking at-home outpatient use of the same compound, branded BXCL501. The FDA has assigned that sNDA a PDUFA action date of 14 November 2026, a milestone BioXcel says it intends to continue supporting through the sale process.
The deal
Teva will serve as the sole "stalking horse" bidder under Section 363 of the US Bankruptcy Code. That designation establishes a baseline offer price, giving competing bidders a floor to beat in an open court-supervised auction. The structure is designed to maximise proceeds for creditors and other stakeholders rather than guarantee a Teva acquisition outright. BioXcel did not disclose the financial terms of Teva's stalking-horse bid.
To fund operations during the proceedings, BioXcel has secured a $19 million debtor-in-possession (DIP) facility from its existing secured lenders, subject to court approval. The company said the facility is expected to cover ordinary-course operations, Chapter 11 process costs, and obligations arising after the filing date. The company's advisers include law firms Cooley LLP and Young Conaway Stargatt & Taylor, financial adviser MERU and investment banker MTS Health Partners.
Chief executive Vimal Mehta said the Chapter 11 route emerged from "a comprehensive review of strategic alternatives" and described it as "a clear framework to pursue a value-maximising transaction." The company said IGALMI remains commercially available and that patient supply will continue uninterrupted.
Market context
BioXcel's filing is a stark illustration of the funding pressures facing commercial-stage neuroscience biotechs. Dexmedetomidine-based agitation treatment occupies a relatively narrow acute-care niche, and building the commercial infrastructure to reach hospital and emergency settings requires sustained investment that many small-cap biotechs have struggled to maintain after the 2021–2022 funding cycle contracted sharply. BioXcel had been seeking a commercial partner or acquirer for some time before the Chapter 11 filing.
For Teva, IGALMI offers an already-approved CNS asset with a near-term regulatory catalyst in the form of the at-home use sNDA. The Israeli generics-and-specialty giant has been methodically rebuilding its branded specialty pipeline following years of debt restructuring and generic drug pricing pressures; a dexmedetomidine sublingual film fits its established focus on CNS and complex formulations.
The November PDUFA date adds urgency to the auction timeline. If the at-home indication is approved before a sale is completed, it could materially alter the asset's commercial value and attract additional auction interest from specialty pharma bidders with direct-to-consumer or outpatient psychiatry capabilities. Observers will also watch whether BXCL501's Breakthrough Therapy designation for agitation associated with Alzheimer's dementia is treated as a transferable asset or lapses in the process.
BioXcel's oncology subsidiary, OnkosXcel Therapeutics, is included in the Chapter 11 filing and would be available to bidders as part of any comprehensive offer, though the release contained no detail on the status of its programmes.